News Insulet Corporation

Equities

PODD

US45784P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
173.9 ^USD	-0.73%		+2.29%	-19.84%

Mar. 20	US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	MT
Mar. 20	Insulet Names Ana Maria Chadwick Finance Chief	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024	Apr. 03	BU
US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	Mar. 20	MT
Insulet Names Ana Maria Chadwick Finance Chief	Mar. 20	MT
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer	Mar. 20	BU
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024	Mar. 20	CI
Insulet Corporation Announces Chief Financial Officer Changes	Mar. 20	CI
3M Board Approves Healthcare Unit Spinoff -- Update	Mar. 08	DJ
Transcript : Insulet Corporation - Special Call	Mar. 08
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy	Mar. 08	MT
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy	Mar. 08	BU
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)	Mar. 08	CI
Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial at the 17th International Conference on Advanced Technologies and Treatments for Diabetes	Mar. 06	AQ
Transcript : Insulet Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:35 AM	Mar. 05
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	Mar. 05	BU
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes	Mar. 05	CI
Stocks in motion: Alphabet drops as Microsoft signs another AI partnership	Feb. 26
Barclays Trims Insulet Price Target to $213 From $214, Maintains Equal Weight Rating	Feb. 26	MT
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024	Feb. 23	AQ
Insulet forecasts weak annual revenue growth; shares drop	Feb. 22	RE
Insulet Q4 Adjusted Earnings, Revenue Increase; Q1, 2024 Revenue Outlook Set	Feb. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Insulet Corporation

Equities

PODD

US45784P1012

Summary

Filters